Neuropeptides: Relevance in treatment of depression and anxiety disorders

Drug News and Perspectives

Volumn 22, Issue 6, 2009, Pages 319-324

  Madaan, Vishal ^a   Wilson, Daniel R ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ANTIDEPRESSANT AGENT; APREPITANT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; FLUOXETINE; GALANIN; GALANIN RECEPTOR ANTAGONIST; L 759274; NEUROPEPTIDE; NEUROPEPTIDE Y; PLACEBO; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VOFOPITANT;

ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PROTEIN FUNCTION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; HUMANS; NEUROPEPTIDES;

EID: 70350539236     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.6.1395255     Document Type: Review

References (52)

1. Murphy, TK., Segarra, A., Storch, E.A. and Goodman, W.K. SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 2008, 20(2): 203-208
2. Nemeroff, C.B. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003, 37(4): 133-146
3. Belzung, C., Yalcin, I., Griebel, G., Surget, A. and Leman, S. Neuropeptides in psychiatric diseases: An overview with a particular focus on depression and anxiety disorders. CNS Neurol Disord Drug Targets 2006, 5(2): 135-145 (Pubitemid 43796616)
4. Holmgren, S. and Jensen, J. Evolution of vertebrate neuropeptides. Brain Res Bull 2001, 55(6): 723-735
5. Kieffer, B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 1995, 15(6): 615-635 (Pubitemid 26019815)
6. Norman, T.R. Prospects for the treatment of depression. Aust N Z J Psychiatry 2006, 40(5): 394-401.
7. Holmes, A., Heilig, M., Rupniak, N.M., Steckler, T. and Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003, 24(11): 580-588 (Pubitemid 37357142)
8. Rosenkranz, M.A. Substance P at the nexus of mind and body in chronic inflammation and affective disorders. Psychol Bull 2007, 133(6): 1007-1037
9. Kramer, M.S., Cutler, N., Feighner, J. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281(5383): 1640-1645 (Pubitemid 28435572)
10. Rupniak, N.M., Carlson, E.J., Webb, J.K. et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the sub- stance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001, 12(6-7): 497-508.
11. Cheeta, S., Tucci, S., Sandhu, J., Williams, A.R., Rupniak, N.M. and File, S.E. Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 2001, 915(2): 170-175 (Pubitemid 32947032)
12. Kramer, M.S. Update on substance P (NK-1 receptor) antagonists in clinical trials for depression. Neuropeptides 2000, 34(5): 255.
13. Kramer, M.S., Winokur, A., Kelsey, J. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29(2): 385-392 (Pubitemid 38180456)
14. Substance P antagonist in the treatment of posttraumatic stress disorder. ClinicalTrials. gov Identifier NCT00383786. Accessed June 22, 2008.
15. Role of substance P in post-traumatic stress disorder. ClinicalTrials.gov Identifier NCT00102102. Accessed June 22, 2008.
16. Carvajal, C., Dumont, Y. and Quirion, R. Neuropeptide Y: Role in emotion and alcohol dependence. CNS Neurol Disord Drug Targets 2006, 5(2): 181-195
17. Larhammar, D. and Salaneck, E. Molecular evolution of NPY receptor subtypes. Neuropeptides 2004, 38(4): 141-151
18. Michel, M.C., Beck-Sickinger, A., Cox, H. et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998, 50(1): 143-150
19. Jolicoeur, F.B., Bouali, S.M., Fournier, A. and St-Pierre, S. Mapping of hypothalamic sites involved in the effects of NPY on body temperature and food intake. Brain Res Bull 1995, 36(2): 125-129 (Pubitemid 24368326)
20. Antonijevic, I.A., Murck, H., Bohlhalter, S., Frieboes, R.M., Holsboer, F. and Steiger, A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000, 39(8): 1474-1481 (Pubitemid 30249209)
21. Heilig, M., McLeod, S., Brot, M. et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993, 8(4): 357-363 (Pubitemid 23162961)
22. Sajdyk, T.J., Schober, D.A., Smiley, D.L. and Gehlert, D.R. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav 2002, 71(3): 419-423
23. Redrobe, J.P., Dumont, Y., Fournier, A. and Quirion, R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26(5): 615-624 (Pubitemid 34260980)
24. Palmiter, R.D., Erickson, J.C., Hollopeter, G., Baraban, S.C. and Schwartz, M.W. Life without neuropeptide Y. Recent Prog Horm Res 1998, 53: 163-199
25. Vezzani, A., Sperk, G. and Colmers, W.F. Neuropeptide Y: Emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999, 22(1): 25-30. (Pubitemid 29130080)
26. Kehne, J.H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007, 6(3): 163-182 (Pubitemid 46916249)
27. Hauger, R.L., Risbrough, V., Brauns, O. and Dautzenberg, F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006, 5(4): 453-479 (Pubitemid 44203356)
28. Grigoriadis, D.E. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005, 9(4): 651-684 (Pubitemid 41131672)
29. Timpl, P., Spanagel, R., Sillaber, I. et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin- releasing hormone receptor 1. Nat Genet 1998, 19(2): 162-166 (Pubitemid 28248798)
30. Heinrichs, S.C., De Souza, E.B., Schulteis, G., Lapsansky, J.L. and Grigoriadis, D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002, 27(2): 194-202. (Pubitemid 34686971)
31. Kasckow, J.W., Baker, D. and Geracioti, T.D. Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001, 22(5): 845-851 (Pubitemid 32397737)
32. Gold, P.W. and Chrousos, G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 2002, 7(3): 254-275
33. Gutman, D.A., Owens, M.J., Skelton, K.H., Thrivikraman, K.V. and Nemeroff, C.B. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 2003, 304(2): 874-880
34. Zobel, A.W., Nickel, T., Künzel, H.E. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000, 34(3): 171-181 (Pubitemid 30364916)
35. Valdez, G.R. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs 2006, 20(11): 887-896
36. Frank, E. and Landgraf, R. The vasopressin system - from antidiuresis to psychopathology. Eur J Pharmacol 2008, 583(2-3): 226-242
37. Landgraf, R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 2006, 5(2): 167-179
38. Zhou, J.N., Riemersma, R.F., Unmehopa, U.A. et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001, 58(7): 655-662
39. Keck, M.E., Welt, T., Müller, M.B. et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003, 28(2): 235-243
40. Holsboer, F. and Barden, N. Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 1996, 17(2): 187-205.
41. de Wied, D. and Sigling, H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 2002, 4(5-6): 453-468
42. Goekoop, J.G., de Winter, R.P., de Rijk, R., Zwinderman, K.H., Frankhuijzen-Sierevogel, A. and Wiegant, V.M. Depression with above- normal plasma vasopressin: Validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Res 2006, 141(2): 201-211
43. de Kloet, C.S., Vermetten, E., Geuze, E., Wiegant, V.M. and Westenberg, H.G. Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. J Psychiatr Res 2008, 42(3): 192-198 (Pubitemid 350266721)
44. Kuteeva, E., Hökfelt, T., Wardi, T. and Ogren, S.O. Galanin - 25 years with a multitalented neuropeptide: Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci 2008, 65(12): 1854-1863
45. Lu, X., Sharkey, L. and Bartfai, T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 2007, 6(3): 183-192
46. Wrenn, C.C. and Crawley, J.N. Pharmacological evidence supporting a role for galanin in cognition and affect. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25(1): 283-299
47. Morilak, D.A., Cecchi, M. and Khoshbouei, H. Interactions of norepinephrine and galanin in the central amygdala and lateral bed nucleus of the stria terminales modulate the behavioral response to acute stress. Life Sci 2003, 73(6): 715-726 (Pubitemid 36703266)
48. Holmes, A., Kinney, J.W., Wrenn, C.C. et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 2003, 28(6): 1031-1044
49. Yoshitake, T., Reenilä, I., Ogren, S.O., Hökfelt, T and Kehr, J. Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci Lett 2003, 339(3): 239-242 (Pubitemid 36299009)
50. Lu, X., Barr, A.M., Kinney, J.W., Sanna, P., Conti, B., Behrens, M.M. and Bartfai, T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci U S A 2005, 102(3): 874-879 (Pubitemid 40282758)
51. Lu, X., Ross, B., Sanchez-Alavez, M., Zorrilla, E.P. and Bartfai, T. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 2008, 42(4): 387-397
52. Kuteeva, E., Wardi, T., Lundström, L., Sollenberg, U., Langel, U. and Hökfelt, T. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/ stress-related genes at the cell body level. Neuropsychopharmacology 2008, 33(11): 2573-2585